POST ASCO Round-up - Olivier and Prasad discuss the top abstracts from the ASCO 2024 meeting

Vinay Prasad, MD MPH; Physician & Professor
Hematologist/ Oncologist
Professor of Epidemiology, Biostatistics and Medicine
Author of 500+ Peer Reviewed papers, 2 Books, 2 Podcasts, 100+ op-eds.
If you want to contact me, do it here: www.vinayakkpra...
Instagram: / vprasadmdmph
Google Scholar: scholar.google...
Substack: vinayprasadmdm...
Podcast: podcasts.apple...
Personal Website: www.vinayakkprasad.com
Laboratory Website: www.vkprasadlab.com
Podcast Website: www.plenarysessionpodcast.com
Academic Publications: www.vinayakkpra...
Follow me on:
Twitter @vprasadmdmph

[@reginamemoriesforever-vc8ql]

Loved Vinay’s commentary regarding the standing ovation as typical of the pagentry of these conferences that mostly are big show for big pharma. It mostly works for pharma not for medicine.

[@derpmcghee]

Was looking forward to this, hope you do this going forward for more conferences.

[@barbaraberwick8993]

20.6 months OS. Please evaluate current treatments of all cancers and what the OS are. Many people would not feel that adding 3 months or 20 months is enough to justify the loss of quality of life, but everyone is left not knowing what to do.

[@dietmarhaudegen3932]

In regards to Ipi/NIvo. Havent you published a paper a month or two ago, where you found that Ipi/Nivo benefits patients with PDL1 neg compared to Nivo alone and that this benefit drives the overall OS benefit of Ipi/Nivo vs Nivo?

[@thegamejunkie1]

👍

[@reginamemoriesforever-vc8ql]

It’s actually quite scary what they are doing to patients… Sh*ty trials that are biased and mostly designed to serve the interests of pharma, some posing serious ethical issues, it’s quite unsettling and to Vinay’s point: is it time to change how things are done? This has gone too far… 😢

[@seandejesus623]

First